Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Pramlintide approval date?
Atorvastatin side effects heart palpitations?
Novartis patent term dabrafenib?
Are there specific stretches to avoid while on lipitor?
Abbvie humira patent cliff navigation success?

Estimate vyzulta generic available?

See the DrugPatentWatch profile for vyzulta

Short answer:
As of now there is no generic version of Vyzulta (palovarotene) on the market, and the earliest that a generic could realistically be expected is around 2029‑2030—roughly 7 years after the original FDA approval.

Why that timeline?

Factor Explanation
FDA approval date Vyzulta was approved in December 2023 for heterotopic ossification associated with traumatic injury and for patients with fibrodysplasia ossificans progressiva (FOP).
Orphan‑drug exclusivity The drug was granted 7‑year market exclusivity under the U.S. Orphan Drug Act. During this period the FDA will not approve any competing generic.
Generic filing window Once the exclusivity period expires, other manufacturers can file an Abbreviated New Drug Application (ANDA). The FDA then reviews the ANDA, which normally takes 10–12 months.
Typical earliest generic entry 7 years after approval → December 2030. Add the usual 1‑year review → 2029‑2030 is the earliest realistic window.
No early “competing generic” pathway Unlike drugs that lose exclusivity earlier (e.g., due to patent expiry or failed patents), Vyzulta’s orphan status locks out generic entry until the statutory period ends.

What if a company wants an earlier generic?

  • Competing Generic (CG) pathway: The FDA allows a CG to be approved before the exclusivity ends if the generic company demonstrates that the original drug’s patent or exclusivity can be overcome. However, this requires a strong legal challenge and is rarely granted for orphan drugs.
  • Orphan Drug Generic Competition (ODGC): The FDA’s ODGC program lets generics enter the market during the exclusivity period if the original drug has a “reasonable chance” of failure in the clinical trial. Vyzulta’s clinical data are robust, so an ODGC filing would be unlikely to succeed.

In short, the regulatory environment is not conducive to an early generic launch.

Practical implications for patients & clinicians

What you’ll see Why it matters
Current price Vyzulta is a high‑cost specialty drug (often > $100,000/year).
Insurance coverage Many insurers require prior authorization; cost‑sharing may be high.
Generic future Once a generic is approved, prices could drop dramatically—potentially 70‑90 % lower than the brand price, improving access for patients.
Monitoring Keep an eye on the FDA’s Drugs@FDA database and the FDA Generic Drug Database; updates about ANDA approvals appear there.

Bottom line

  • No generic is available today.
  • Earliest realistic availability: ~2029‑2030 (7 years after FDA approval + review).
  • Until then: Vyzulta will remain the sole approved therapy for its indicated conditions, and its pricing and insurance handling will continue to apply.

Feel free to let me know if you’d like more detailed information on insurance navigation, cost‑sharing options, or how to monitor generic approval timelines!



Other Questions About Vyzulta :

Vyzulta quanto vende? Cupon para vyzulta? How much is vyzulta? Vyzulta generic availability 2026? Vyzulta damla etken maddesi? Vyzulta owner? Vyzulta generic?